India's Supreme Court has dismissed with costs Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law (scripintelligence.com, 1 April 2013).
The detailed ruling from the court shows that the beta crystalline form of imatinib mesylate failed in both the tests...